The SEPT9 V2 gene transcription's gamma promoter region, which is differentially methylated in patients with CRC, is analyzed as part of the Septin 9 test, which has been shown to be effective in the non-invasive and accurate screening of CRC. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.